487 related articles for article (PubMed ID: 27653290)
1. Neurologic complications of immune checkpoint inhibitors.
Hottinger AF
Curr Opin Neurol; 2016 Dec; 29(6):806-812. PubMed ID: 27653290
[TBL] [Abstract][Full Text] [Related]
2. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
Makarious D; Horwood K; Coward JIG
Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
4. [Immune-related adverse events by immune checkpoint inhibitors].
Kadono T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
[TBL] [Abstract][Full Text] [Related]
5. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
6. [Managing the Adverse Effects Related to Immune Checkpoint Inhibitors].
Kuo HH; Chen WW
Hu Li Za Zhi; 2018 Jun; 65(3):88-95. PubMed ID: 29790143
[TBL] [Abstract][Full Text] [Related]
7. PD-1 checkpoint inhibition: Toxicities and management.
Hahn AW; Gill DM; Agarwal N; Maughan BL
Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
[TBL] [Abstract][Full Text] [Related]
8. Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: A case report and literature review.
Chen JH; Lee KY; Hu CJ; Chung CC
Medicine (Baltimore); 2017 Dec; 96(50):e9262. PubMed ID: 29390370
[TBL] [Abstract][Full Text] [Related]
9. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
10. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
12. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
Supakornnumporn S; Katirji B
J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
[TBL] [Abstract][Full Text] [Related]
13. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
[TBL] [Abstract][Full Text] [Related]
15. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
Liao B; Shroff S; Kamiya-Matsuoka C; Tummala S
Neuro Oncol; 2014 Apr; 16(4):589-93. PubMed ID: 24482447
[TBL] [Abstract][Full Text] [Related]
16. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
Lau KH; Kumar A; Yang IH; Nowak RJ
Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
[TBL] [Abstract][Full Text] [Related]
17. Safety of pembrolizumab for the treatment of melanoma.
Martin-Liberal J; Kordbacheh T; Larkin J
Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
[TBL] [Abstract][Full Text] [Related]
18. Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.
Friedman CF; Proverbs-Singh TA; Postow MA
JAMA Oncol; 2016 Oct; 2(10):1346-1353. PubMed ID: 27367787
[TBL] [Abstract][Full Text] [Related]
19. Immune-mediated respiratory adverse events of checkpoint inhibitors.
Tabchi S; Messier C; Blais N
Curr Opin Oncol; 2016 Jul; 28(4):269-77. PubMed ID: 27138570
[TBL] [Abstract][Full Text] [Related]
20. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS.
Ji HH; Tang XW; Dong Z; Song L; Jia YT
Clin Drug Investig; 2019 Mar; 39(3):319-330. PubMed ID: 30674039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]